IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells.


Autoria(s): Barbey C.; Baumgaertner P.; Devevre E.; Rubio-Godoy V.; Derre L.; Bricard G.; Guillaume P.; Luescher I.F.; Liénard D.; Cerottini J.C.; Romero P.; Rufer N.; Speiser D.E.
Data(s)

2007

Resumo

Activated CD8 T cells develop cytotoxicity against autologous cells bearing foreign Ags and self/tumor Ags. However, self-specific cytolysis needs to be kept under control to avoid overwhelming immunopathology. After peptide vaccination of melanoma patients, we studied molecular and functional properties of T cell subsets specific for the self/tumor Ag Melan-A/MART-1. Ex vivo analysis revealed three Ag-specific effector memory (EM) populations, as follows: CD28-negative EM (EM28(-)) T cells strongly expressing granzyme/perforin, and two EM28(+) subsets, one with high and the other with low level expression of these cytotoxic proteins. For further functional characterization, we generated 117 stable CD8 T cell clones by ex vivo flow cytometry-based sorting of these subsets. All EM28(-)-derived clones lysed target cells with high efficacy. In contrast, EM28(+)-derived clones were heterogenous, and could be classified in two groups, one with high and the other with low killing capacity, correlating with granzyme/perforin expression. High and low killer phenotypes remained surprisingly stable for several months. However, strongly increased granzyme expression and cytotoxicity were observed after exposure to IL-12. Thus, the data reveal a newly identified subset of CD28(+) conditional killer T cells. Because CD28 can mediate strong costimulatory signals, tight cytotoxicity control, as shown in this study through IL-12, may be particularly important for subsets of T cells expressing CD28.

Identificador

http://serval.unil.ch/?id=serval:BIB_34A31269CA86

isbn:0022-1767 (Print)

pmid:17339453

doi:10.4049/​jimmunol.178.6.3566

isiid:000244942400028

http://my.unil.ch/serval/document/BIB_34A31269CA86.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_34A31269CA862

Idioma(s)

en

Direitos

info:eu-repo/semantics/openAccess

Fonte

Journal of Immunology, vol. 178, no. 6, pp. 3566-3574

Palavras-Chave #Adjuvants, Immunologic/pharmacology; Antigens, CD28/biosynthesis; Antigens, CD28/immunology; Antigens, Neoplasm/administration & dosage; Antigens, Neoplasm/immunology; CD8-Positive T-Lymphocytes/immunology; CD8-Positive T-Lymphocytes/metabolism; Clone Cells; Female; Granzymes/biosynthesis; Granzymes/immunology; Humans; Immunity, Cellular/drug effects; Interleukin-12/pharmacology; Isoantigens/administration & dosage; Isoantigens/immunology; Male; Melanoma/immunology; Melanoma/metabolism; Membrane Glycoproteins/biosynthesis; Membrane Glycoproteins/immunology; Peptide Fragments/administration & dosage; Peptide Fragments/immunology; Perforin; Pore Forming Cytotoxic Proteins/biosynthesis; Pore Forming Cytotoxic Proteins/immunology; Time Factors; Vaccination
Tipo

info:eu-repo/semantics/article

article